000267556 001__ 267556
000267556 005__ 20240229154921.0
000267556 0247_ $$2doi$$a10.3390/cancers15030991
000267556 0247_ $$2pmid$$apmid:36765946
000267556 0247_ $$2altmetric$$aaltmetric:142446887
000267556 037__ $$aDKFZ-2023-00334
000267556 041__ $$aEnglish
000267556 082__ $$a610
000267556 1001_ $$00000-0003-4139-1979$$aTichanek, Filip$$b0
000267556 245__ $$aSurvival in Colon, Rectal and Small Intestinal Cancers in the Nordic Countries through a Half Century.
000267556 260__ $$aBasel$$bMDPI$$c2023
000267556 3367_ $$2DRIVER$$aarticle
000267556 3367_ $$2DataCite$$aOutput Types/Journal article
000267556 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1677578713_27832
000267556 3367_ $$2BibTeX$$aARTICLE
000267556 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000267556 3367_ $$00$$2EndNote$$aJournal Article
000267556 500__ $$a#LA:C020#
000267556 520__ $$aBackground: Survival studies in intestinal cancers have generally shown favorable development, but few studies have been able to pinpoint the timing of the changes in survival over an extended period. Here, we compared the relative survival rates for colon, rectal and small intestinal cancers from Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE). Design: Relative 1-, 5- and 5/1-year conditional survival data were obtained from the NORDCAN database for the years 1971-2020. Results: The 50-year survival patterns were country-specific. For colon and rectal cancers, the slopes of survival curves bended upwards for DK, were almost linear for NO and bended downwards for FI and SE; 5-year survival was the highest in DK. Survival in small intestinal cancer was initially below colon and rectal cancers but in FI and NO it caught up toward the end of the follow-up. Conclusions: Relative survival in intestinal cancers has developed well in the Nordic countries, and DK is an example of a country which in 20 years was able to achieve excellent survival rates in colon and rectal cancers. In the other countries, the increase in survival curves for colon and rectal cancer has slowed down, which may be a challenge posed by metastatic cancers.
000267556 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000267556 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000267556 650_7 $$2Other$$aincidence
000267556 650_7 $$2Other$$aprognosis
000267556 650_7 $$2Other$$arelative survival
000267556 650_7 $$2Other$$arisk factors
000267556 650_7 $$2Other$$atreatment
000267556 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000267556 7001_ $$aLiska, Vaclav$$b2
000267556 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b3
000267556 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b4$$eLast author$$udkfz
000267556 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15030991$$gVol. 15, no. 3, p. 991 -$$n3$$p991$$tCancers$$v15$$x2072-6694$$y2023
000267556 909CO $$ooai:inrepo02.dkfz.de:267556$$pVDB
000267556 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000267556 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000267556 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000267556 9141_ $$y2023
000267556 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-24T07:56:58Z
000267556 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000267556 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000267556 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000267556 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000267556 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000267556 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000267556 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000267556 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000267556 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000267556 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000267556 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000267556 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000267556 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000267556 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000267556 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000267556 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000267556 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000267556 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000267556 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000267556 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000267556 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000267556 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000267556 980__ $$ajournal
000267556 980__ $$aVDB
000267556 980__ $$aI:(DE-He78)B062-20160331
000267556 980__ $$aI:(DE-He78)HD01-20160331
000267556 980__ $$aI:(DE-He78)C020-20160331
000267556 980__ $$aUNRESTRICTED